Proteínas pro-apoptóticas y anti-apoptóticas como factores de pronóstico en Linfoma B difuso de célula grande en adultos
Pro-apoptotic and anti-apoptotic proteins as prognostic factors in diffuse large B-cell lymphoma in adults. Objective. Ourpurpose was to evaluate the expression of antiapoptotic proteins Bcl-2 and Bcl-xL,and pro-apoptotic proteins Bad and Bax and theirassociation with survival, in patients with DLBC...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Pontificia Universidad Javeriana
2010-12-01
|
| Series: | Universitas Scientiarum |
| Subjects: | |
| Online Access: | http://revistas.javeriana.edu.co/index.php/scientarium/article/view/1358/825 |
| Summary: | Pro-apoptotic and anti-apoptotic proteins as prognostic factors in diffuse large B-cell lymphoma in adults. Objective. Ourpurpose was to evaluate the expression of antiapoptotic proteins Bcl-2 and Bcl-xL,and pro-apoptotic proteins Bad and Bax and theirassociation with survival, in patients with DLBCL. Materials and methods. We analyzed biopsies from 28 patients diagnosed withDLBCL. The expression of the apoptotic regulators was assessed by western blot. The association between protein expression andsurvival was analyzed by the Kaplan-Meier method and the log-rank test. Results. Bcl-2, Bak, Bad and Bcl-xL proteins were expressedin 78.8, 71.4, 64.3 and 50% of the DLBCL cases, respectively. We found no association between the presence of proteins or theirexpression levels and overall survival. Both Bad and Bcl-xL were associated with higher disease-free survival (33.3% vs. 20.0%, p LR test= 0,003; 42.9% vs. 14.3%, p LR test= 0.03, respectively). High expression levels of Bad and Bcl-xL were associated with a higher disease-free survival (35.7% vs. 21.4%, p LR test= 0.012 y 42.9% vs. 14.3%, p LR test= 0.045, respectively). Conclusion. Given that expression of the Bad protein in tumors was related to a higher disease-free survival, patients with low expression levels of Bad could be candidates in future therapies oriented towards the inhibition of the anti-apoptotic proteins Bcl-xL and Bcl-2 by using molecules that bind specifically to the BH3 domain. |
|---|---|
| ISSN: | 0122-7483 2027-1352 |